Background
Acute myeloid leukemia (AML) is a clonal aggressive hematological malignant disease with clinical and genetic heterogeneity [
1,
2]. Although treatment of AML has made a significant achievement, the majority of patients experience a relapse of primary AML and develop resistance to chemotherapy [
3]. In particular, elderly patients with AML are ineligible for intensive chemotherapy and their 5-year overall survival rate is only 5–15% [
4]. It remains a major challenge in AML management due to refractoriness, relapse and drug resistance.
The B-cell lymphoma-2 (BCL‐2) is dysregulated in AML and its overexpression mediates therapeutic resistance and poor clinical prognosis, which makes BCL-2 an encouraging therapeutic target [
5‐
7]. ABT-199 (venetoclax/GDC-0199), selectively targeting BCL-2, is a novel BCL-2 homology domains 3 (BH3) mimetic agent. In vitro studies had confirmed the remarkable anti-leukemic effect of ABT-199 in either chemotherapy-sensitive or chemotherapy-resistant AML cells, and more importantly, it was reported to eliminate leukemia stem cells [
8,
9]. The combination of ABT-199 with hypomethylating agents (decitabine or azacitidine) achieved complete remission (CR) or CR with incomplete blood count recovery (CRi) in 67% of elderly patients with AML [
10]. 54% of elderly AML adults who received combined regimen of ABT-199 and low-dose cytarabine (LDAC) achieved CR/CRi [
11]. In addition, clinical trials of ABT-199 in combination with FMS-like tyrosine kinase 3 (FLT3) inhibitors, isocitrate dehydrogenase (IDH1/2) inhibitors and other agents on AML have been launched [
12].
APG-2575 (lisaftoclax) is a BCL-2 selective inhibitor independently developed by Suzhou Ascentage Pharma, several clinical trials have been initiated in hematologic malignancies [
13]. The results of the phase I trial (NCT03537482) showed that APG-2575 had anti-tumor activity and tolerable safety in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL), small lymphocytic lymphoma (SLL) and other hematologic tumors [
14]. APG-2575 combined with rituximab/ibrutinib or HHT/ azacytidine is currently being tested clinically for SLL/CLL or R/R AML (NCT04494503, NCT04501120). APG-2575 in combination with Bruton’s tyrosine kinase (BTK) inhibitor (ibrutinib) or MDM2-p53 inhibitor (APG-115) showed a synergistic anti-tumor effect in diffuse large B-cell lymphoma (DLBCL) [
15]. In addition, combination therapy of APG-2575 and tyrosine kinase inhibitor (TKI) (olverembatinib/HQP1351) showed synergistic anti-leukemic effects in FLT3-ITD mutant AML [
13]. Myeloid cell leukemia-1 (MCL-1) was highly expressed in multiple hematological malignancies [
16], and was shown to mediate the development of hematological malignancies, including AML [
17,
18]. Moreover, up-regulation of MCL-1 expression was observed during treatment with ABT-199, leading to the development of drug resistance [
16,
19].
Homoharringtonine (HHT) is an alkaloid obtained from the
Cephalotaxus hainanensis. It is successfully applied in the treatment of hematological diseases due to its effective anti-tumor activity [
20,
21]. In our previous study, we found that HHT down-regulated the BCL-2 and MCL-1 expression [
22], making us hypothesize combination of HHT with APG-2575 may enhance the response and reverse the APG-2575 resistance in AML cells.
In the present study, we evaluated the synergistic anti-AML effect of combined treatment of APG-2575 and HHT in AML. Our results revealed that the addition of HHT potentiated the anti-leukemic effect of APG-2575 in AML cell lines and primary AML cells in vitro and in vivo. Mechanistically, HHT inhibited the Phosphoinositide-3-Kinase/Protein kinase B/Glycogen synthase kinase-3 (PI3K/AKT/GSK3β) signaling pathway, leading to MCL-1 dual phosphorylated and degraded, which overcame the resistance of APG-2575 mediated by overexpressed MCL-1. In conclusion, our results support further exploring the effect of the combination regimen of HHT and APG-2575 in AML treatment.
Materials and methods
Materials
APG-2575 was provided by Ascentage Pharma (Suzhou) Co., Ltd and ABT-199 was purchased from Selleck Chemicals (Houston, TX, USA). HHT was purchased from Sigma-Aldrich (St. Louis, MO, USA). The antibodies GAPDH (#5174), PARP (#9532), Caspase3 and Cleaved-Caspase3 (Cleaved-C3) (#9662), Caspase7 and Cleaved-Caspase7 (Cleaved-C7) (#9494), PI3K (p85α) (#4257), AKT (#4691), AKT (Ser473) (#4060), GSK3β (#9315), GSK3β (Ser9) (#9323), MCL-1 (#94296), MCL-1 (Thr163) (#14765) and MCL-1 (Thr163/Ser159) (#4579) were purchased from Cell Signaling Technology (CST, Beverly, MA, USA).
Cell lines and primary cells
MV4-11 cell line was kindly endowed by Professor R. Bhatia (City of Hope National Medical Center, Duarte, CA, USA). THP-1, HL-60, U937 and OCI-AML3 cell lines were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences. Kasumi-1 cell line was gifted by Professor Chen Saijuan (Shanghai Institute of Hematology, Shanghai, China). MV4-11 cells were maintained in Iscove’s Modified Dulbecco’s medium (IMDM, Gibco, Billings, MT, USA) supplemented with 10% fetal bovine serum (FBS, Gibco), and THP-1, HL-60, U937 and OCI-AML3 cells were cultured in Roswell Park Memorial Institute 1640 (RPMI 1640, Gibco) medium supplemented with 10% FBS at 37 °C in a humidified incubator containing 5% CO2.
Bone marrow samples were obtained from AML patients following written informed consent. Mononuclear cells were isolated by Ficoll-Hypaque (Sigma-Aldrich, St. Louis, MO, USA) density gradient centrifugation. The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Zhejiang University, China.
Cell viability assay
20,000 AML cells (cell density of 2.0 × 10
5 cells/ml) or 100,000 primary AML cells (cell density of 1.0 × 10
6 cells/ml) were seeded in a 96-well plate and treated with designated drugs for the 24 or 48 h. Then 10 ul MTS solution (Promega CellTitre 96, Promega Corporation, Madison, WI, USA (5 mg/ml) was added by incubation for additional 3–4 h at 37℃. The plates were measured at an absorbance of 490 nm. IC50 values and combination index (CI) were calculated by CalcuSyn Software (Biosoft, Cambridge, UK) (CI: < 1, synergism; > 1, antagonism; = 1, additivity). That program was based on the following equation: q = E
A+B / (E
A + E
B—E
A × E
B), where E
A and E
B are the inhibition rate of group A and group B, respectively, and E
A+B is the inhibition rate of group A combined with B (q: > 1.15, synergism; < 0.85, antagonism; 0.85–1.15, additivity) [
23,
24].
Flow-cytometric analysis of apoptosis
The extent of apoptosis was assessed through an apoptosis detection kit (Beyotime Institute of Biotechnology, Hangzhou, China). Cells were treated with drugs for 24 h, and then harvested and washed with phosphate buffered saline (PBS). According to the manufacturer’s instruction, after resuspending in binding buffer and staining with Annexin V-FITC (Annexin-V) and propidium iodide (PI) in dark at room temperature for 15 min, cells were subjected to FACScan™ flow cytometer (Becton Dickinson, San Diego, CA, USA). Data were presented as percentages of Annexin V + cells.
Western blot analysis
Cells were harvested and washed in PBS, and then lysed in radioimmunoprecipitation (RIPA) buffer in the presence of protease and phosphatase inhibitor (Cell Signaling Technology (CST), Beverly, MA, USA)) on ice for 30 min. Cells were centrifuged at 12,000g for 15 min at 4 °C to pellet cell debris. The protein concentration was determined using BCA reagent. Equal protein was electrophoresed in 10% SDS-PAGE (Life Technologies, Carlsbad, CA, USA) and transferred to a PVDF membrane (Millipore, Billerica, MA, USA). The transblotted membranes were blocked with 5% non-fat milk in TBS-T for 1 h and then incubated with primary antibodies overnight at 4 ℃. Then the membranes were washed thrice with TBS-T buffer, 15 min each time, followed by secondary HRP-conjugated antibody (CST, Beverly, MA, USA) for 1 h at room temperature. The target proteins were visualized using an ECL detection kit (Amersham, Little Chalfont, UK) and analyzed using IMAGE LABTM software (Bio-Rad Laboratories, Hercules, CA, USA).
AML xenograft model
BALB/c Nude mice (female, 4–6 weeks of age, weight 17–24 g) were purchased from Shanghai Lingchang Biotechnology Co., Ltd. (Shanghai, China) and Hangzhou Medical College Laboratory animal center. MV4-11 cells were resuspended in PBS (1 × 106 cells/mouse), and then subcutaneously injected into the right back of BALB/c Nude mice to establish a subcutaneous xenograft tumor model. When the tumor volume reached to 50–150 mm3, the mice were randomly divided into 6 groups (vehicle control, 50 mg/kg APG-2575, 50 mg/kg ABT-199, 1 mg/kg HHT, 50 mg/kg APG-2575 + 1 mg/kg HHT, 50 mg/kg ABT-199 + 1 mg/kg HHT). The administration was started on the day of grouping (ie D1; APG-2575/1BT-199, PO, QDx21D; HHT, IP, QDx14D). The mouse body weight and tumor size were measured twice a week during the experiment. After the administration, all mice were killed by cervical dislocation. In addition, OCI-AML3 cells were injected subcutaneously on the left back of BALB/c Nude mice, and the other operations referred to the above.
Tumor volume (TV) was calculated as: TV = L × W
2/2, Where L and W represent the length and width of the tumor, respectively. The relative tumor volume (RTV) was: RTV = Vt/V1. V1 is the TV on the first day of administration (Day1) and Vt is the TV at the time of measurement (Day t). The evaluation index of anti-leukemic effect was the relative tumor proliferation rate: (T/C (%) = (T
RTV/C
RTV) × 100%) [T
RTV: the RTV of the treatment group, C
RTV: the RTV of the vehicle control group]. Synergy analysis was measured by using the formula [
25]: expected value = (A/C) × (B/C) [actual value = (AB)/C; A: RTV of A drug; B: RTV of B drug; C = The RTV of the vehicle control group; AB = the RTV of the combined administration group]. The synergy index = expected value/actual value; ratio > 1, indicating that the two drugs have a synergistic effect; ratio = 1, indicating that the two drugs have an additive effect; ratio < 1, indicating that the two drugs have a weaker than additive effect. Change of body weight (%) = (measured weight-weight at grouping)/weight at grouping × 100%. In addition, complete regression (CR), partial regression (PR) and stable disease (SD) among the number of animals in each group represented the remission rate. T/C (%) ≤ 42% and statistical analysis P < 0.05 is effective. If the weight of the mouse drops by more than 20% or the number of drug-related death exceeds 20%, the drug dose is considered to be severely toxic.
All animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Suzhou GenePharma (Approval No: IACUC-2021003) and Hangzhou Medical College Laboratory animal center (Approval No: ZJCLA-IACUC-20120003).
Statistical analyses
The one-way ANOVA test were used to assess statistical significance. P value < 0.05 was considered statistically significant. Experiments were presented as the means ± standard deviation (SD) in three independent experiments. The results of animal experiments and cell inhibition assay in primary AML samples were presented as the means ± standard error of the mean (SEM). Statistical analyses were conducted using Prism software v8.3.0 (GraphPad Software, La Jolla, CA, USA) and IBM SPSS Statistics 24 (Armonk, NY, USA).
Discussion
AML is a genetically heterogeneous disorder characterized by a poor survival rate. Regardless of whether regimens combine conventional therapies with multiple novel target drugs or hematopoietic stem cell transplantation (HSCT), AML remains an incurable malignancy of the bone marrow. New regimens with better tolerance and efficacy, less toxicity and fewer side effects are urgently needed. On June 7, 2021, Ascentage Pharma Ascent Pharmaceuticals presented the latest clinical progress of the new generation of Bcl-2 inhibitor APG-2575 at the ASCO meeting. Among 15 patients with R/R CLL/SLL, 12 cases achieved partial remission (PR) and the overall remission rate (ORR) was as high as 80.0%. No dose-limiting toxicity (DLT) was observed at 1200 mg and no tumor lysis syndrome occurred [
15]. It means that there are great potentials for clinical development of single drug and combination therapy of APG-2575, which will bring better options for patients. MCL-1 plays a vital role in the development of hematological malignancies and high expression of MCL-1 is associated with BCL-2 inhibitor resistance. Our previous studies identified that HHT could reduce MCL-1 and exert significant anti-leukemic activity [
26,
27]. Therefore, we propose the combined application of APG-2575 and HHT for the treatment of AML in order to reverse the resistance of APG-2575.
In this study, we first compared the anti-leukemic effect of APG-2575 and ABT-199 and the results suggested that the two agents were comparable in inhibiting AML cells growth. Next, we found HHT in combination with APG-2575 displayed an excellent anti-leukemic effect. APG-2575 showed dose-dependent growth inhibition and accelerate apoptosis when administrated as a monotherapy, and the combined regimen exhibited more obvious synergistic activity, as evidenced by the activation of PARP and caspase family members. Studies had shown that tumor cells with high expression of anti-apoptotic protein MCL-1 have primary resistance to the BCL-2 selective inhibitor [
28]. Interestingly, the two agents exerted more significant growth inhibition and apoptosis in OCI-AML3 cells (inherent resistance to APG-2575) and AML patient samples (De novo or R/R). These results demonstrated that HHT enhanced the anti-leukemic effect of APG-2575, suggesting HHT as a potential drug to overcome the resistance of APG-2575.
According to the cell experiments in vitro, MV4-11 cells are moderately sensitive to APG-2575. Therefore, we first used human MV4-11 cells to establish a mouse xenograft tumor model to evaluate the anti-tumor effect of the combination of APG-2575 and HHT. The results suggested that APG-2575 and ABT-199 have equally anti-leukemic effects in vivo. The data proved that APG-2575 combined with HHT had a synergistic effect in vivo. And we further confirmed co-administration of APG-2575/HHT also exerting synergistic anti-leukemic effect in the OCI-AML3 xenograft model. Together, these above results verified that the combination of APG-2575 and HHT has a significant synergistic anti-AML effect in vitro and in vivo, indicating that this combined regimen could bring clinical benefits to AML patients.
GSK3β has been reported to be related to p-MCL-1 (Thr163/Ser159), and the double-phosphorylated MCL-1 (Thr163/Ser159) is degraded through the ubiquitinase pathway. Phosphorylation at serine 9 weakens GSK3β constitutive activity [
29,
30]. Our results suggested that single-agent APG-2575 could not down-regulate p-GSK3β (S9), thereby preventing the conversion of p-MCL-1 (Thr163) to p-MCL-1(Thr163/Ser159). The accumulated p-MCL-1 (Thr163) could stabilize the structure of MCL-1 and made MCL-1 being more difficult to be degraded. APG-2575 combined with HHT can inhibit the PI3K/AKT/GSK3β signaling pathway. Because p-GSK3β (Ser9) is down-regulated, it was beneficial to the conversion of mono-phosphorylated p-MCL-1(Thr163) to double-phosphorylated p-MCL-1(Thr163/Ser159), and further degradation through ubiquitinase. The inhibition of the signaling pathway leads to the decrease of MCL-1 content and reverses the resistance of APG-2575.
Conclusion
Some studies have reported that high expression of MCL-1 was related to non-remission following ABT-199 treatment, and the original resistance in AML cells could reverse by co-administration of MCL-1 inhibitor. In this study, HHT combined with APG-2575 treatment could reduce the level of MCL-1. Overall, HHT combined with APG-2575 could overcome the resistance to APG-2575 in AML, and these preclinical results provided strong evidence for the treatment of AML patients with APG-2575 combined with HHT.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.